Saturday, October 31, 2026

Carnival Stock Soars 31%+ In 21 Sessions: Investors Rejoice!

ViaNews Editorial Team

December 26, 2023

Carnival Stock Soars 31%+ In 21 Sessions: Investors Rejoice!

(VIANEWS) - Carnival shares have experienced an extraordinary surge, rising by 31.37% over 21 sessions from EUR14.41 to EUR18.93 despite remaining 4.1% below their 52-week high of EUR19.74; furthermore, two consecutive sessions of gains has increased the NYSE index by 0.27% to EUR16,770.45.

About Carnival

Carnival Corporation & plc operates over 90 ships operating under various brand names, such as AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line Princess Cruises P&O Cruises (Australia and UK), P&O Cruises (Australia & UK), Seabourn and Seabourn. Their ports offer port destinations as well as services, hotels lodges glass dome railcars motorcoaches motorcoaches motorcoaches as well as port destinations in various countries across North America Continental Europe the UK Australia New Zealand Asia and internationally - starting back at their founding back in 1972 based out of Miami Florida

Yearly Analysis

Carnival (CARN.L) stock is currently trading at EUR18.93, above its 52-week high of EUR19.74 and significantly above its low of EUR7.55; this indicates investors' confidence in Carnival's performance. Carnival is projected to experience a sales growth rate of 13.3% this year, which is considered high. However, in 2019 its expected rate should moderate slightly to 4.5%. These projections should be seen as estimates and subject to change over time. Carnival currently holds an EBITDA ratio of 2.51, signalling that they are producing a healthy profit margin and strong financial standing. Investors will find this positive indicator of profitability. Carnival's stock appears to be performing well and investors appear positive regarding its growth prospects. However, investors must keep in mind that stock markets can be unpredictable; thus it is prudent for any individual or institution seeking investment decisions to conduct extensive research prior to making any definitive investment decisions.

Technical Analysis

Carnival Corporation & plc (CCL) has seen its stock price steadily increase over time, currently standing at EUR17.79 - this figure surpasses both its 50-day moving average of EUR14.47 and 200-day moving average of EUR13.79 by over 20% respectively. Carnival reported volume trading increased 19.09% year over year to 38,240,404; this indicates growing investor enthusiasm. Carnival stock has experienced some level of volatility over recent months and quarters; its intraday variation average for last week, last month and last quarter were respectively 1.52%, 1.54% and 2.51%, with its highest amplitude being 3.88% (week), 2.44% (month) and 2.51% (quarter), showing signs of movement within its stock price. This indicates it may have seen recent price swings that might indicate volatility for itself. According to the stochastic oscillator, which serves as an effective indicator for overbought and oversold conditions, Carnival's stock is currently considered oversold (=20), signalling potential undervaluation in its current price and offering investors an investment opportunity. Overall, Carnival appears to be on an upward trend with rising stock price, above-average trading volume, and potentially undervalued position. Investors should exercise caution when making any investments decisions and conduct further research before making their final choice.

Quarter Analysis

Based on this data, the growth outlook for this stock appears positive. According to estimates for both current quarter and next quarter growth estimates for the company is 72.7% and 106.5% respectively indicating revenue will likely grow substantially over time. Additionally, the year-on-year quarterly revenue growth for the twelve trailing months stands at 40.6% - this represents continuous expansion throughout this past year and indicates an upward trajectory going forward. Overall, investors might wish to consider this stock as a potential investment opportunity if they're searching for companies with strong growth prospects. However, investors should keep in mind that growth projections are just estimates and may not always pan out accordingly; due diligence must always be conducted prior to making any definitive investment decisions.

Equity Analysis

According to Carnival's financial data, its trailing twelve month EPS stands at EUR-0.06, reflecting negative earnings for shareholders. This indicates that Carnival is currently not producing profits for them. Additionally, the company has generated an negative Return on Equity (ROE) over the last twelve months of -1.06%; meaning for every EUR1 of shareholder's equity it generated a loss of EUR-0.106. A negative ROE indicates that its equity is not being utilized efficiently to produce profits and yield results. Given Carnival's poor earnings and ROE figures, investors should exercise extreme caution when making any investment decisions involving this company. Before making any definitive investments decisions or investments of their own accord. It is crucial that they closely observe financial performance of management as they make efforts to enhance profitability before making their own.

More news about Carnival (CCL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com